Life coaching requires no mental health education, and it sometimes attracts former therapists who have lost their license to practice, reports ProPublica. Other states making news are New York, Iowa, ...

Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target of $970.00. The company’s shares closed last Friday at ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. The Big Pharma announced Thursday that its LillyDirect platform will now connect U.S. users to both in-person and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

European Committee Says Lilly Alzheimer's Drug Shouldn't Get Marketing Approval A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, diabetes and migraine medicines. Patients will now be able to use ...